281 related articles for article (PubMed ID: 32212232)
21. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.
Adam S; Koch-Gallenkamp L; Bertram H; Eberle A; Holleczek B; Pritzkuleit R; Waldeyer-Sauerland M; Waldmann A; Zeissig SR; Rohrmann S; Brenner H; Arndt V
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13076. PubMed ID: 31050091
[TBL] [Abstract][Full Text] [Related]
23. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
[TBL] [Abstract][Full Text] [Related]
24. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
25. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
26. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
Hoffman RM; Lo M; Clark JA; Albertsen PC; Barry MJ; Goodman M; Penson DF; Stanford JL; Stroup AM; Hamilton AS
J Clin Oncol; 2017 Jul; 35(20):2306-2314. PubMed ID: 28493812
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
28. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
29. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
30. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
31. Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
McDonald AC; Gernand J; Geyer NR; Wu H; Yang Y; Wang M
Cancer; 2022 May; 128(9):1832-1839. PubMed ID: 35195279
[TBL] [Abstract][Full Text] [Related]
32. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
33. Treatment of early-stage prostate cancer among rural and urban patients.
Baldwin LM; Andrilla CH; Porter MP; Rosenblatt RA; Patel S; Doescher MP
Cancer; 2013 Aug; 119(16):3067-75. PubMed ID: 23765584
[TBL] [Abstract][Full Text] [Related]
34. Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
Djaladat H; Amini E; Xu W; Cai J; Daneshmand S; Lieskovsky G
Prostate; 2017 May; 77(7):743-748. PubMed ID: 28144967
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
[TBL] [Abstract][Full Text] [Related]
36. Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.
Gunnarsson O; Schelin S; Brudin L; Carlsson S; Damber JE
Scand J Urol; 2019; 53(2-3):102-108. PubMed ID: 30990112
[No Abstract] [Full Text] [Related]
37. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
38. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
39. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
40. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
Dall'Era MA; Lo MJ; Chen J; Cress R; Hamilton AS
Cancer; 2018 May; 124(9):1921-1928. PubMed ID: 29499075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]